“Teva welcomes the Secretary of State’s vision for building a digital NHS which empowers patients, clinicians and carers to better manage their health. Given the significant financial, clinical and demographic challenges facing the country, the NHS should aim to be the global leader in the use of digital healthcare innovation and technology. However, like the Secretary of State, we need to be realistic about the challenges in achieving this vision – to be successful we need to build a digital ecosystem underpinned by meaningful partnerships between businesses, the NHS and Government.
We believe that the definitive shift in healthcare will come when we are successful in combining the delivery of healthcare services, the effective use of medicines and digital technology. We are keen to work in partnership with the NHS to develop digital health solutions that help patients by making health and social care more sustainable in the face of rising demand. Our work with the NHS in Sheffield as part of its Test Beds programme showcases our commitment to partnering with the NHS to address sustainability challenges, and we hope to expand this work to other parts of the country.”
Teva published research earlier this week showing that a growing number of inexperienced patients and UK carers are searching online for support and trustworthy information. With over 70% of carers themselves suffering from a long term condition, the NHS desperately needs to accelerate the adoption of digital that supports the needs of carers and patients.
# ENDS #
Notes to Editors:
About Teva’s research
Teva published the results of a global survey of 3,086* carers which has cast new light on the struggles carers in the UK face today. The analysis reveals the majority of caregivers in the UK are relatively new to caring, with most taking care of someone for five years or less, furthermore, the data reveals 34% are millennials (between the ages of 18 – 34). More than half of carers surveyed in the UK said they turn to online search engines to find information on topics related to health, however, the majority have no trust in these platforms and find advice difficult to understand. The analysis has highlighted the growing needs of carers who are ‘just about managing’, and whose role will only become more critical as people in the UK live longer. Teva undertook this global and UK analysis of caregivers to illustrate the growing role carers are playing in health and social care.
About Teva at the NHS Health and Care Expo 2017 (11 – 12 September 2017):
As overall sponsors of this year’s Expo, Teva is proud to be collaborating with NHS England and partners on a number of initiatives to further develop transformation and help patients live better days. This includes partnering with the National Health Service (NHS) on its ‘Perfect Patient Pathway’ Test Bed in Sheffield, UK, which aims to understand how an innovative combination of digital technology, behavioural change science and patient support services can be of benefit to patients in the self-management of their asthma condition. The Digital Health Zone being held at the NHS Health and Care Expo 2017 will give visitors the opportunity to find out more about the crucial role of technology and data in modernising and future-proofing the NHS, as well as highlighting case studies of programmes already in place that are delivering improved outcomes for patients. For more information, visit http://www.tevauk.com/nhs-expo.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2015 amounted to $19.7 billion. For more information, visit www.tevapharm.com.